If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksItaconix Plc Regulatory News (ITX)

Share Price Information for Itaconix Plc (ITX)

Share Price is delayed by 15 minutes
Get Live Data
109.50    0.00 (0.00%)
Bid:
107.00
Ask:
112.00
Spread: 5.00 (4.673%)
Market Cap: £14.77m
ITX Live PriceLast checked at - London Stock Exchange

Intraday Itaconix Plc Share Chart

Board Appointment

10 Jul 2012 08:09

RNS Number : 2592H
Revolymer PLC
10 July 2012
 



10 July 2012

Revolymer plc

("Revolymer" or "the Group")

Julian Heslop to Join the Board of Revolymer

 

Former CFO of GSK to become an Independent Non-Executive Director

 

Revolymer, the British polymer company developing products for a number of high value fast moving consumer goods ("FMCG") markets, is pleased to announce that, as a consequence of the Group's admission to the AIM Market today, the appointment of Julian Heslop to the Board has now become effective.

 

Julian served as Chief Financial Officer of GlaxoSmithKline plc ("GSK") between April 2005 and March 2011. He was also Chairman of ViiV Healthcare Limited until March 2011. He served as Senior Vice President, Operations Controller of GSK between January 2001 and March 2005 and as Financial Controller of Glaxo Wellcome plc from April 1998 to December 2000. Prior to this, Julian had senior finance roles at Grand Metropolitan plc and Imperial Brewing and Leisure. He is a Fellow of the Institute of Chartered Accountants in England and Wales.

 

Julian Heslop, commenting on his appointment said, "I am delighted to be joining the Board of Revolymer. I look forward to playing an active role as the Group seeks to generate significant value from its broad product pipeline by signing a number of licensing deals with important players in the FMCG markets it is targeting."

 

Jack Keenan, Chairman of Revolymer commenting on today's announcement said, "Julian's decision to join the Board of Revolymer, upon its Admission to AIM, is an important endorsement of the Group's technology and the market opportunities that it has chosen to pursue. His financial knowledge and experience in both pharmaceutical and FMCG markets will be extremely valuable as the company seeks to develop its business."

 

Further information on Julian Spenser Heslop as required by AIM Rule 17 and Schedule Two, paragraph (g) of the AIM Rules for Companies is to be found in paragraph 4 of Part VI of the Group's Admission Document which was published on 4 July 2012 and available at www.revolymer.com

 

 

Ends

 

 

Revolymer plc

+44 (0) 1244 283 500

Roger Pettman

Rob Cridland

 

Panmure Gordon (UK) Limited

+44 (0) 20 7459 3600

Callum Stewart / Adam James (Corporate Finance)

Adam Pollock / Charles Leigh-Pemberton (Corporate Broking)

 

Citigate Dewe Rogerson

+44 (0)20 7638 9571

Ginny Pulbrook / David Dible

 

About Revolymer

 

Revolymer® is a technology company that designs, develops and formulates novel polymers to improve the performance of existing consumer products within the FMCG markets. Revolymer's strategy is to generate significant and growing revenue streams by licensing its unique and proprietary technologies to manufacturers and marketers within the global high value FMCG industry. Current applications for the Group's technologies are in the confectionery chewing gum and medicated chewing gum (together "gum") markets; and in coatings & adhesives, household products and personal care (together "consumer specialties").

www.revolymer.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOARLMATMBAMBTT
Date   Source Headline
9th Apr 20211:07 pmRNSIssue of Shares, Director/PDMR Dealings
30th Mar 20217:00 amRNSFull Year Results Ended 31 December 2020
24th Mar 202111:06 amRNSSecond Price Monitoring Extn
24th Mar 202111:00 amRNSPrice Monitoring Extension
24th Mar 20217:00 amRNSNotice of Final Results and Investor Presentation
23rd Mar 20212:06 pmRNSSecond Price Monitoring Extn
23rd Mar 20212:00 pmRNSPrice Monitoring Extension
23rd Mar 202111:05 amRNSSecond Price Monitoring Extn
23rd Mar 202111:00 amRNSPrice Monitoring Extension
28th Jan 20212:06 pmRNSSecond Price Monitoring Extn
28th Jan 20212:01 pmRNSPrice Monitoring Extension
27th Jan 202111:06 amRNSSecond Price Monitoring Extn
27th Jan 202111:00 amRNSPrice Monitoring Extension
26th Jan 202111:05 amRNSSecond Price Monitoring Extn
26th Jan 202111:00 amRNSPrice Monitoring Extension
26th Jan 20217:00 amRNSTrading Update for the year ended 31 December 2020
21st Jan 202111:05 amRNSSecond Price Monitoring Extn
21st Jan 202111:01 amRNSPrice Monitoring Extension
18th Jan 20212:06 pmRNSSecond Price Monitoring Extn
18th Jan 20212:01 pmRNSPrice Monitoring Extension
14th Jan 20214:41 pmRNSSecond Price Monitoring Extn
14th Jan 20214:35 pmRNSPrice Monitoring Extension
14th Jan 20212:06 pmRNSSecond Price Monitoring Extn
14th Jan 20212:01 pmRNSPrice Monitoring Extension
14th Jan 20217:00 amRNSAppointment of new Vice President, Operations
8th Jan 202111:06 amRNSSecond Price Monitoring Extn
8th Jan 202111:00 amRNSPrice Monitoring Extension
30th Dec 202011:05 amRNSSecond Price Monitoring Extn
30th Dec 202011:00 amRNSPrice Monitoring Extension
29th Dec 20204:41 pmRNSSecond Price Monitoring Extn
29th Dec 20204:36 pmRNSPrice Monitoring Extension
3rd Nov 20207:00 amRNSAppointment of New Marketing and Sales Executive
28th Oct 20207:00 amRNSHalf Year Results
23rd Oct 20202:30 pmRNSResult of AGM
21st Oct 20207:00 amRNSNotice of Interim Results
13th Oct 202011:06 amRNSSecond Price Monitoring Extn
13th Oct 202011:00 amRNSPrice Monitoring Extension
2nd Oct 20204:35 pmRNSPrice Monitoring Extension
2nd Oct 20203:17 pmRNSCorrection to Full Year Results
30th Sep 20207:00 amRNSFull Year Results
16th Sep 20208:00 amRNSHolding(s) in Company
15th Sep 20207:00 amRNSNotice of Results
22nd Jul 20207:14 amRNSH1 2020 Trading Update
17th Jul 20201:36 pmRNSHolding(s) in Company
17th Jul 202011:18 amRNSHolding(s) in Company
15th Jul 20203:04 pmRNSDirector/PDMR Shareholding
14th Jul 202012:51 pmRNSResult of General Meeting
26th Jun 20206:01 pmRNSNotice of GM and Posting of Circular
24th Jun 20203:33 pmRNSResult of Fundraise
24th Jun 20207:55 amRNSClose of Accelerated Bookbuild

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.